首页> 外文OA文献 >Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

【2h】

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

机译：DACETUZUMAB加里康妥昔单抗，IFOSFAMIDE，CARBOPLATIN和ETOPOSIDE作为弥漫性大型B细胞淋巴瘤患者的救助治疗，RITUXIMAB，环磷酰胺，多码霉素，长春碱和泼尼松酮：随机，双盲，安慰剂控制相2B试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Luis Fayad; Stephen M. Ansell; Ranjana Advani; Bertrand Coiffier; Robert Stuart; Nancy L. Bartlett; Andres Forero-Torres; Kazimierz Kuliczkowski; David Belada; Edmund Ng; Jonathan G. Drachman;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial [J] . Fayad Luis, Ansell Stephen M., Advani Ranjana, Leukemia and lymphoma . 2015,第9期

机译：Dacetuzumab联合利妥昔单抗，异环磷酰胺，卡铂和依托泊苷作为利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松龙复治的弥漫性大B细胞淋巴瘤复发的抢救疗法：一项随机，双盲，安慰剂对照的2b期试验
2. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT] (NHL-14) [J] . Fridrik Michael A., Jaeger Ulrich, Petzer Andreas, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：与利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松龙相比，利妥昔单抗，环磷酰胺，非聚乙二醇脂质体阿霉素，长春新碱和泼尼松龙在前线治疗弥漫性大B细胞淋巴瘤患者中的心脏毒性来自奥地利癌症药物的一项随机III期研究治疗工作组[Arbeitsgemeinschaft Medikamentose肿瘤治疗AGMT]（NHL-14）
3. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. [J] . Maruyama D, Watanabe T, Maeshima AM, International journal of hematology . 2010,第5期

机译：改良的环磷酰胺，长春新碱，阿霉素和甲氨蝶呤（CODOX-M）/异环磷酰胺，依托泊苷和阿糖胞苷（IVAC）治疗在有或没有利妥昔单抗的日本成年Burkitt淋巴瘤（BL）和B细胞淋巴瘤患者中无法分类，其特征介于两者之间弥漫性大B细胞淋巴瘤和BL。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma [O] . Anas Younes, Laurie H. Sehn, Peter Johnson, -1

机译：依鲁替尼和利妥昔单抗加环磷酰胺阿霉素长春新碱和泼尼松在非女性中心性B细胞弥漫性大B细胞淋巴瘤的III期随机试验
6. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma [O] . Anas Younes, Laurie H. Sehn, Peter Johnson, 2019

机译：无伊布勒替尼和蓖麻素苷加环磷酰胺，多柔比蛋白，长春脉和泼尼松在非生发中心B细胞扩散大B细胞淋巴瘤中的随机化期III试验

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

著录项

相似文献

相关主题

期刊订阅